{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Renal+Cancer&page=5",
    "query": {
      "condition": "Metastatic Renal Cancer",
      "page": 5
    },
    "page_size": 10
  },
  "pagination": {
    "page": 5,
    "page_size": 10,
    "total_count": 830,
    "total_pages": 83,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Renal+Cancer&page=6&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Renal+Cancer&page=4&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-08T03:30:17.383Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT07227415",
      "title": "Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Carcinoma, Renal Cell",
        "Advanced Renal Cell Carcinoma",
        "Renal Cancer",
        "Renal Neoplasm",
        "Clear Cell Renal Cell Carcinoma",
        "Metastatic Renal Cell Carcinoma",
        "Clear-cell Metastatic Renal Cell Carcinoma",
        "Carcinoma, Renal Cell Metastasis",
        "Advanced or Metastatic Renal Cell Carcinoma",
        "Carcinoma, Renal Cell, Advanced",
        "Metastatic Renal Cell Cancer",
        "Metastatic Renal Cell Carcinoma ( mRCC)",
        "Metastatic/Advanced Renal Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "PF-08634404",
          "type": "DRUG"
        },
        {
          "name": "Ipilimumab",
          "type": "DRUG"
        },
        {
          "name": "Axitinib",
          "type": "DRUG"
        },
        {
          "name": "Casdatifan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 224,
      "start_date": "2026-02-10",
      "completion_date": "2028-11-01",
      "has_results": false,
      "last_update_posted_date": "2026-09-17",
      "last_synced_at": "2026-10-08T03:30:17.383Z",
      "location_count": 140,
      "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Fayetteville, Arkansas + 84 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Rogers",
          "state": "Arkansas"
        },
        {
          "city": "Springdale",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07227415"
    },
    {
      "nct_id": "NCT02567409",
      "title": "Cisplatin and Gemcitabine Hydrochloride With or Without Berzosertib in Treating Patients With Metastatic Urothelial Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Bladder Urothelial Carcinoma",
        "Metastatic Renal Pelvis and Ureter Urothelial Carcinoma",
        "Metastatic Ureter Urothelial Carcinoma",
        "Stage IV Bladder Urothelial Carcinoma AJCC v7"
      ],
      "interventions": [
        {
          "name": "Berzosertib",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine Hydrochloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 87,
      "start_date": "2017-01-31",
      "completion_date": "2023-04-25",
      "has_results": true,
      "last_update_posted_date": "2025-03-03",
      "last_synced_at": "2026-10-08T03:30:17.383Z",
      "location_count": 39,
      "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Duarte, California + 28 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02567409"
    },
    {
      "nct_id": "NCT00854620",
      "title": "Safety and Toxicity Study of Sorafenib in Patients With Kidney Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Carcinoma, Renal Cell",
        "Kidney Disease",
        "Kidney Cancer"
      ],
      "interventions": [
        {
          "name": "Sorafenib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Stanford University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 9,
      "start_date": "2007-12",
      "completion_date": "2011-01",
      "has_results": true,
      "last_update_posted_date": "2015-06-19",
      "last_synced_at": "2026-10-08T03:30:17.383Z",
      "location_count": 1,
      "location_summary": "Stanford, California",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00854620"
    },
    {
      "nct_id": "NCT03126331",
      "title": "Intermittent Therapy in Metastatic Renal Cell Carcinoma Patients Treated With Ipilimumab and Nivolumab",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Renal Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Nivolumab",
          "type": "DRUG"
        },
        {
          "name": "Ipilimumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Case Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 26,
      "start_date": "2017-08-03",
      "completion_date": "2023-10-24",
      "has_results": false,
      "last_update_posted_date": "2024-03-18",
      "last_synced_at": "2026-10-08T03:30:17.383Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03126331"
    },
    {
      "nct_id": "NCT01846520",
      "title": "Family Caregiver Palliative Care Intervention in Supporting Caregivers of Patients With Stage II-IV Gastrointestinal, Gynecologic, Urologic and Lung Cancers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Healthy Subject",
        "Localized Transitional Cell Cancer of the Renal Pelvis and Ureter",
        "Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter",
        "Psychosocial Effects of Cancer and Its Treatment",
        "Recurrent Bladder Cancer",
        "Recurrent Cervical Cancer",
        "Recurrent Colon Cancer",
        "Recurrent Gastric Cancer",
        "Recurrent Ovarian Epithelial Cancer",
        "Recurrent Ovarian Germ Cell Tumor",
        "Recurrent Pancreatic Cancer",
        "Recurrent Rectal Cancer",
        "Recurrent Renal Cell Cancer",
        "Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter",
        "Recurrent Urethral Cancer",
        "Recurrent Uterine Sarcoma",
        "Regional Transitional Cell Cancer of the Renal Pelvis and Ureter",
        "Stage II Bladder Cancer",
        "Stage II Renal Cell Cancer",
        "Stage II Urethral Cancer",
        "Stage IIA Cervical Cancer",
        "Stage IIA Colon Cancer",
        "Stage IIA Gastric Cancer",
        "Stage IIA Ovarian Epithelial Cancer",
        "Stage IIA Ovarian Germ Cell Tumor",
        "Stage IIA Pancreatic Cancer",
        "Stage IIA Rectal Cancer",
        "Stage IIA Uterine Sarcoma",
        "Stage IIB Cervical Cancer",
        "Stage IIB Colon Cancer",
        "Stage IIB Gastric Cancer",
        "Stage IIB Ovarian Epithelial Cancer",
        "Stage IIB Ovarian Germ Cell Tumor",
        "Stage IIB Pancreatic Cancer",
        "Stage IIB Rectal Cancer",
        "Stage IIB Uterine Sarcoma",
        "Stage IIC Colon Cancer",
        "Stage IIC Ovarian Epithelial Cancer",
        "Stage IIC Ovarian Germ Cell Tumor",
        "Stage IIC Rectal Cancer",
        "Stage III Bladder Cancer",
        "Stage III Pancreatic Cancer",
        "Stage III Renal Cell Cancer",
        "Stage III Urethral Cancer",
        "Stage IIIA Cervical Cancer",
        "Stage IIIA Colon Cancer",
        "Stage IIIA Gastric Cancer",
        "Stage IIIA Ovarian Epithelial Cancer",
        "Stage IIIA Ovarian Germ Cell Tumor",
        "Stage IIIA Rectal Cancer",
        "Stage IIIA Uterine Sarcoma",
        "Stage IIIB Cervical Cancer",
        "Stage IIIB Colon Cancer",
        "Stage IIIB Gastric Cancer",
        "Stage IIIB Ovarian Epithelial Cancer",
        "Stage IIIB Ovarian Germ Cell Tumor",
        "Stage IIIB Rectal Cancer",
        "Stage IIIB Uterine Sarcoma",
        "Stage IIIC Colon Cancer",
        "Stage IIIC Gastric Cancer",
        "Stage IIIC Ovarian Epithelial Cancer",
        "Stage IIIC Ovarian Germ Cell Tumor",
        "Stage IIIC Rectal Cancer",
        "Stage IIIC Uterine Sarcoma",
        "Stage IV Bladder Cancer",
        "Stage IV Gastric Cancer",
        "Stage IV Ovarian Epithelial Cancer",
        "Stage IV Ovarian Germ Cell Tumor",
        "Stage IV Pancreatic Cancer",
        "Stage IV Renal Cell Cancer",
        "Stage IV Urethral Cancer",
        "Stage IVA Cervical Cancer",
        "Stage IVA Colon Cancer",
        "Stage IVA Rectal Cancer",
        "Stage IVA Uterine Sarcoma",
        "Stage IVB Cervical Cancer",
        "Stage IVB Colon Cancer",
        "Stage IVB Rectal Cancer",
        "Stage IVB Uterine Sarcoma",
        "Ureter Cancer",
        "Stage IIA Lung Carcinoma",
        "Stage IIB Lung Carcinoma",
        "Stage IIIA Lung Carcinoma",
        "Stage IIIB Lung Carcinoma"
      ],
      "interventions": [
        {
          "name": "educational intervention",
          "type": "OTHER"
        },
        {
          "name": "telephone-based intervention",
          "type": "BEHAVIORAL"
        },
        {
          "name": "quality-of-life assessment",
          "type": "PROCEDURE"
        },
        {
          "name": "questionnaire administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER",
        "BEHAVIORAL",
        "PROCEDURE"
      ],
      "sponsor": "City of Hope Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 200,
      "start_date": "2013-10-29",
      "completion_date": "2019-05-23",
      "has_results": false,
      "last_update_posted_date": "2026-10-01",
      "last_synced_at": "2026-10-08T03:30:17.383Z",
      "location_count": 1,
      "location_summary": "Duarte, California",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01846520"
    },
    {
      "nct_id": "NCT00045370",
      "title": "Chemotherapy and Biological Therapy in Treating Patients With Locally Advanced or Metastatic Kidney Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Kidney Cancer"
      ],
      "interventions": [
        {
          "name": "recombinant interferon alfa",
          "type": "BIOLOGICAL"
        },
        {
          "name": "temsirolimus",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": "2002-04",
      "completion_date": "2003-11",
      "has_results": false,
      "last_update_posted_date": "2013-06-05",
      "last_synced_at": "2026-10-08T03:30:17.383Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00045370"
    },
    {
      "nct_id": "NCT04006522",
      "title": "89Zr-DFO-Atezolizumab ImmunoPET/CT in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Renal Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "89Zr-DFO-Atezolizumab",
          "type": "DRUG"
        },
        {
          "name": "Positron Emission Tomography/Computed Tomography",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "James Brugarolas",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 46,
      "start_date": "2019-10-02",
      "completion_date": "2027-08-31",
      "has_results": false,
      "last_update_posted_date": "2026-08-31",
      "last_synced_at": "2026-10-08T03:30:17.383Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04006522"
    },
    {
      "nct_id": "NCT02315066",
      "title": "Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Neoplasms"
      ],
      "interventions": [
        {
          "name": "PF-04518600",
          "type": "DRUG"
        },
        {
          "name": "PF-04518600 plus PF-05082566",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 174,
      "start_date": "2015-04-23",
      "completion_date": "2020-11-12",
      "has_results": true,
      "last_update_posted_date": "2022-04-21",
      "last_synced_at": "2026-10-08T03:30:17.383Z",
      "location_count": 24,
      "location_summary": "Los Angeles, California • Newport Beach, California • Santa Monica, California + 9 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02315066"
    },
    {
      "nct_id": "NCT04903873",
      "title": "A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Solid Tumor",
        "Renal Cell Cancer Metastatic",
        "Non-Small Cell Lung Cancer",
        "Renal Cell Carcinoma",
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "EU101",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eutilex",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 110,
      "start_date": "2021-05-31",
      "completion_date": "2025-12",
      "has_results": false,
      "last_update_posted_date": "2024-03-15",
      "last_synced_at": "2026-10-08T03:30:17.383Z",
      "location_count": 2,
      "location_summary": "Philadelphia, Pennsylvania • Dallas, Texas",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04903873"
    },
    {
      "nct_id": "NCT02761057",
      "title": "Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Locally Advanced Papillary Renal Cell Carcinoma",
        "Metastatic Papillary Renal Cell Carcinoma",
        "Stage III Renal Cell Cancer AJCC v7",
        "Stage IV Renal Cell Cancer AJCC v7",
        "Type 1 Papillary Renal Cell Carcinoma",
        "Type 2 Papillary Renal Cell Carcinoma",
        "Unresectable Renal Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Bone Scan",
          "type": "PROCEDURE"
        },
        {
          "name": "Cabozantinib S-malate",
          "type": "DRUG"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Crizotinib",
          "type": "DRUG"
        },
        {
          "name": "Savolitinib",
          "type": "DRUG"
        },
        {
          "name": "Sunitinib Malate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 152,
      "start_date": "2016-07-25",
      "completion_date": "2023-10-19",
      "has_results": true,
      "last_update_posted_date": "2025-01-13",
      "last_synced_at": "2026-10-08T03:30:17.383Z",
      "location_count": 586,
      "location_summary": "Anchorage, Alaska • Kingman, Arizona • Fort Smith, Arkansas + 361 more",
      "locations": [
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02761057"
    }
  ]
}